Samuel Ojelel
ID: UNCST-2019-R000996
|
Tropical Important Plant Areas of Uganda
REFNo: NS479ES
(i) To assess conservation status of priority plant species to guide Identification of Important Plant Areas
(ii) To promote sustainable use and protection of Important Plant Areas by developing partnership with key stakeholders
|
Uganda |
2023-03-24 2:17:32 |
2026-03-24 |
Natural Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Denis Muhangi
ID: UNCST-2020-R014258
|
A STUDY ON CONDOM DEMAND, UTILIZATION, DISTRIBUTION AND DISPOSAL SURVEY 2022
REFNo: SS1605ES
1. To establish the condom demand for both the male and female condom users in the community programming in 61 districts of Uganda
2. To generate information on distribution and utilization of condoms among key, priority and general population in 61 districts of Uganda
3. To generate data to be used to fill gaps in comprehensive condom programming in relation to condom demand, distribution, management and disposal as well as modalities for strengthening condom logistics in Uganda
4. To explore new modalities for strengthening condom logistics among the non-traditional channels of condom distribution in the community.
5. To determine the extent of adherence to the condom waste management and disposal mechanisms developed by MoH,
6. To establish status and opportunities of using the Total Market Approach
|
Uganda |
2023-03-24 2:13:39 |
2026-03-24 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Caroline Nerima
ID:
|
FUNCTIONAL LIMITATIONS AMONG CHILD REFUGEES WITH DEVELOPMENTAL DISABILITIES AND BARRIERS TO EARLY CHILDHOOD INTERVENTION IN A UGANDAN REFUGEE SETTLEMENT.
REFNo: HS2666ES
1. To describe the functional limitations among children aged 1 month to 6 years with developmental disabilities.
2. To describe the early intervention services available for children with developmental disabilities living in refugee camps.
3. To describe the barriers to access to early intervention services for children with developmental disabilities.
|
Uganda |
2023-03-24 2:10:43 |
2026-03-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Winnie Muyindike R
ID: UNCST-2021-R013558
|
Tuberculosis, Alcohol, and Lung Comorbidities (TALC) Study
REFNo: HS2705ES
Qualitatively evaluate factors for tailoring pharmaco-behavioral alcohol and smoking interventions in PLWH being treated for TB. ,Explore how smoking alters the association of past-month heavy drinking and post-TB lung disease progression over time,• Aim 1b. Assess the association of past-month heavy drinking and post-TB lung disease progression over time. This aim uses recent alcohol use (30-day Timeline Followback, PEth) since direct mechanisms (e.g., alcohol toxicity) may drive the physiologic, anatomic, and immunologic outcomes of interest. We define past-month heavy drinking as ≥7 drinks/week (women), ≥14 drinks/week (men) or PEth>200 ng/mL.,• Aim 1a. Determine if past-year hazardous drinking is associated with post-TB lung disease. ,Aim 1. Determine the relationship between hazardous drinking and post-TB lung disease in PLWH.,
|
Uganda |
2023-03-24 2:08:05 |
2026-03-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Denis Muhangi
ID: UNCST-2020-R014258
|
Sustainable Off-Grid Solutions for Pharmacies and Hospitals in Africa (SophiA).
Sub-component 1: Needs Assessment of Hospitals/Health Centre IVs for the Sustainable Off-Grid Solutions
Sub-component 2: Socio-Economic Acceptance and Participation Assessment for Stakeholders
Sub-component 3: Life Cycle Assessment and Sustainability Assessment
REFNo: SS1627ES
Goal of the SophiA Project: To bring environmental, economic, social and health benefits, creating new business and job opportunities through new technological solutions; to support African countries to pursue sustainable pathways of development through a low-carbon, climate resilient and green growth trajectory, leapfrogging fossil fuels and high GWP refrigerant technologies; and to improve the quality of life of populations through better treatment and working conditions in rural and remote health facilities in Africa.
Specific Objectives of the Proposed Studies:
i) To assess the needs from several health stations in order to identify and match the most significant and suitable health station which can be served by one SophiA system, considering different uses, replicability, cost and constraints as pertains energy consumption and solar radiation.
ii) To assess the level of acceptance of the SophiA technological solutions by the relevant stakeholders including beneficiary communities, local leaders, health care providers and managers, district officials, and national level decision makers/policy makers.
iii) To conduct a Life Cycle Assessment (LCA) to evaluate the different environmental impacts and calculate the CO2 emissions for each of the SophiA technology: solar thermal, solar PV, thermal storage, electrical storage, ice storage, refrigerators).
|
Uganda |
2023-03-24 2:04:40 |
2026-03-24 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Esther Nasuuna Michelle
ID:
|
The Epidemiology of Chronic Kidney Disease among young people living with HIV in Uganda
REFNo: HS2578ES
1. To describe the prevalence of CKD among YPLHIV in SSA.
2. To compare the prevalence and associated factors of CKD diagnosed with cystatin C or creatinine-based estimates among YPLHIV in Uganda.
3. To describe the comorbidities associated with CKD among YPLHIV in Uganda.
|
Uganda |
2023-03-22 15:08:26 |
2026-03-22 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Paul Bangirana
ID:
|
Blood-Biomarkers and Risk Factors of Acute Brain Injury associated with Neurodisability in Ugandan Children (BRAIN-Child)
REFNo: HS2628ES
Determine if elevated brain injury biomarkers in pediatric TBI correlate with post-discharge mortality or neurocognitive impairment (NCI) and health-related quality of life outcomes at 6-month follow-up,Determine if biomarkers and risk factors of brain injury elevated in pediatric CM are elevated in pediatric TBI,
|
Uganda |
2023-03-21 3:29:20 |
2026-03-21 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Simon Kasasa
ID: UNCST-2021-R012861
|
A National Survey to Determine the Prevalence of Latent and Active Tuberculosis, COVID-19 and HIV Among Prisoners and Prisons Staff in Uganda Prisons
REFNo: HS2373ES
Overall objective
To determine the burden and associated factors of TB, COVID-19, and HIV among inmates and staff in Uganda prisons in order to generate evidence that will inform future interventions.
Primary objectives
i. To estimate the prevalence and associated factors of LTBI among inmates and staff in the Uganda prisons.
ii. To determine the prevalence and associated factors of active TB disease among inmates and staff in Uganda prisons.
iii. To determine the current burden of COVID-19 among prisoners and staff using an integrated TB and COVID-19 screening and testing approach.
iv. To establish the burden of past COVID-19 infection among prisoners and staff in Uganda prisons.
v. To determine the prevalence of HIV among inmates and staff in Uganda prisons.
vi. To determine HIV program achievement and gaps in the Uganda Prisons in reference to the UNAIDS targets for HIV testing, positive individuals who are on treatment, and PLHIV with suppressed viral load (95-95-95).
|
Uganda |
2023-03-21 3:23:05 |
2026-03-21 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Moreen Kabarungi
ID:
|
A FRAMEWORK TOWARDS THE IMPROVEMENT OF ADOPTION OF BLENDED LEARNING IN HIGHER EDUCATIONAL INSTITUTIONS
CASE STUDY OF SOUTH WESTERN UGANDA.
REFNo: SS1665ES
The main objective of this study is to develop a framework to support the adoption of blended learning in higher educational institutions in south western Uganda.
The specific objectives are;
1. To establish the strengths, weaknesses and elicit the requirements of the existing blended learning frameworks and their level of usage and satisfaction in higher educational institutions.
2. To design a framework that supports the adoption of blended learning in higher educational institutions.
3. To evaluate the feasibility, acceptability and usage of the designed framework of blended learning in higher educational institutions.
|
Uganda |
2023-03-21 3:19:16 |
2026-03-21 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Tonny Ssekamatte
ID: UNCST-2022-R010961
|
Understanding the barriers and facilitators to access and utilisation Sexual and Reproductive Health services among vulnerable/marginalized adolescents and young people in Uganda
REFNo: SS1673ES
To investigate the barriers and facilitators to access and utilisation Sexual and Reproductive Health services among vulnerable/marginalized adolescents and young people in Uganda ,Examine the role of social media/other sources in the spread of information and/or disinformation and how it potentially influences access to and use of SRH services.,Examine the role of social norms in influencing the use/non-use of SRH services among the populations of interest:,Explore the barriers and facilitators to accessing SRH services among vulnerable/marginalized 15–24-year-old adolescents and young people.,
|
Uganda |
2023-03-21 3:16:17 |
2026-03-21 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
.JPG)
|
Annet Nanungi Kabuye
ID:
|
An mhealth framework for cancer surveillance in Uganda
REFNo: HS2695ES
To develop an mhealth data framework for cancer surveillance in Uganda.,
|
Uganda |
2023-03-21 3:06:26 |
2026-03-21 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Elizabeth (Betsy) Ness-Edelstein Ann
ID:
|
Cooperative Development Program Evaluation
REFNo: SS1664ES
Assess how the specific work of Health Partners in Uganda is contributing to the overall program objectives,● Contribute to the evidence base on effective cooperative development approaches.,● Identify the assumptions or gaps in the project’s design or management approach to help inform a new project design,● Illuminate ways in which the entire project is making progress toward the stated Project Purpose or not,
|
USA |
2023-03-21 3:04:41 |
2026-03-21 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Edward Mokooza Kibikyo
ID: UNCST-2020-R014923
|
Understanding Barriers and Facilitators to Establishing Palliative Care Units at Hospitals in Uganda.
REFNo: SS1510ES
4. To identify the facilitators of establishing palliative care units in hospitals in Uganda. ,3. To describe barriers to the establishment of palliative care units in hospitals in Uganda.,2. To document the functionality of existing PC units in hospitals in Uganda. ,1. To determine the proportion of public and private hospitals with PC units.,
|
Uganda |
2023-03-16 13:06:27 |
2026-03-16 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Zhubin Chen
ID:
|
The Impact of Social Health Insurance on the Incentives of Health Care Providers in East Africa: A Mixed-methods Approach
REFNo: SS1574ES
1.1 Describe how social health insurance functions and how health care providers respond to the economic incentives of social health insurance in Rwanda, Kenya, and Uganda
1.2 Pose hypotheses based on 1.1 and test them empirically using nationally representative data
2. Follow different institutional actors (ministry of health, health facilities, NGOs, and community organizations) and describe how they perceive the function of social health insurance in Rwanda, Kenya, and Uganda
3. Compare the impact mechanism of social health insurance in Rwanda, Kenya, and Uganda and document how the impact evolves on different paths and at different stages towards UHC
|
China |
2023-03-16 13:04:14 |
2026-03-16 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Peace Tumuheki Buhwamatsiko
ID:
|
Experiences of students combining work and study at Ugandan universities
REFNo: SS1646ES
To explore experiences of students who combine work and study at both private and public universities in Uganda with a view of making recommendations that will contribute to improving their university education experience and promote inclusive lifelong learning agenda in higher education,To explore and examine the suitable academic and administrative supports for students combining work and study,To explore the classroom learning experiences of students who combine work and study,To uncover the motivations underlying the decision to combine work and study at university and the associated benefits and challenges,
|
Uganda |
2023-03-16 13:02:52 |
2026-03-16 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
.JPG)
|
Victoria Nankabirwa
ID: UNCST-2021-R011871
|
Implementation of an eRegistry Enabled Transition from Four to Eight Antenatal Care Contacts - a Cluster-Randomized Controlled Trial in Mukono and Buikwe, Uganda (eReg4ANC8)
REFNo: HS2662ES
III. Undertake a cRCT of the new ANC8 vs. the current ANC4 schedule for low-risk pregnancies, to estimate its impact on quality of care, health, and satisfaction.,II. To assess and respond to factors across the i-PARIHS and COM-B domains to guide the facilitation of feasibility, acceptability, fidelity, and effectiveness of implementation of digitally enabled ANC8 at scale. ,I. To assess and respond to factors across the PARIHS and COM-B domains to guide the facilitation of feasibility, acceptability, fidelity, and effectiveness of the implementation of DHIS2 eRegistries for ANC at scale. ,
|
Uganda |
2023-03-16 13:01:11 |
2026-03-16 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Victoria Ndyanabangi
ID: UNCST-2021-R012645
|
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability,Acceptability, and Pharmacokinetics of Oral and Long-ActingInjectable Cabotegravir and Rilpivirine in Virologically SuppressedChildren Living with HIV-1, Two to Less Than 12 Years of Age, DAIDSStudy ID #38932 IND # 138754
REFNo: HS2688ES
To propose the weight band dosing of oral cabotegravir (CAB) + oral rilpivirine (RPV)followed by long-acting injectable CAB (CAB LA) + long-acting injectable RPV (RPV LA)in children living with HIV-1, and to describe participant choice and experience with theregimen with or without an oral lead-in period.
To describe the repeat-dose pharmacokinetics of CAB + RPV (oral and injectable)through Week 24
To assess the safety of the oral lead-in of CAB + RPV, and the safety of CAB + RPV (oraland injectable) through Week 24
To assess the safety of CAB + RPV (oral and injectable) through Weeks 48 and 72
To describe the repeat-dose pharmacokinetics of injectable CAB LA + RPV LA throughWeeks 48 and 72
To assess the maintenance of viral suppression of CAB + RPV (oral and injectable)through Weeks 24, 48, and 72
To evaluate the tolerability and acceptability of injectable CAB LA + RPV LA throughWeeks 24, 48, and 72
To describe HIV-1 genotypes and phenotypes for children who experience virologicfailure during study treatment
To assess immunologic activity of CAB + RPV (oral and injectable) through Weeks 24,48, and 72
To describe tolerability and acceptability of 48 weeks of CAB + RPV (oral and injectable)and 44 weeks of CAB LA + RPV LA (injectable only)
To describe the safety and repeat-dose pharmacokinetics of 48 weeks of CAB + RPV(oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only)
To describe the maintenance of viral suppression and immunologic activity of 48 weeks ofCAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only)
To describe HIV-1 genotypes and phenotypes for children who experience virologicfailure during 48 weeks of CAB + RPV (oral and injectable) or during 44 weeks of CABLA + RPV LA (injectable only)
To characterize long-term safety and washout PK through 48 weeks after permanentdiscontinuation of injectable CAB LA + RPV LAV LA
To characterize PK of CAB + RPV oral formulations when dispersed in liquid vs. directly ingested (Weight Bands 3, 4 and 5)
|
Uganda |
2023-03-16 12:55:20 |
2026-03-16 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Charles Batte
ID: UNCST-2021-R013587
|
The impact of COVID-19 on school enrolment and mental health of children in the Manafwa Watershed area in Uganda.
REFNo: HS2725ES
To assess the coping strategies of school-going children in the Manafwa Watershed area during the COVID-19 pandemic.,To assess the post-lockdown mental health status of school-going children in the Manafwa Watershed area. ,To evaluate the effects of COVID-19 lockdown on school enrolment of children in the Manafwa Watershed area.,To assess the impact of COVID-19 and its associated restrictive measures on school enrolment and mental health of children in a disaster-prone area, Manafwa Watershed area, in Eastern Uganda.,
|
Uganda |
2023-03-16 12:51:27 |
2026-03-16 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Jack Richardson Lloyd
ID:
|
The role of social play in the development of wild mountain gorillas in Bwindi Impenetrable National Park, Uganda
REFNo: NS490ES
(1) determine how biological, ecological, and social factors influence amount of time spent in social play.
(2) examine how structural components of play (asymmetry, dominance, play
partnerships, play type) can differentiate between functions.
(3) investigate proposed trade-offs and developmental outcomes of social play.
|
UK |
2023-03-16 12:48:10 |
2026-03-16 |
Natural Sciences |
Non-Clinical Trial |
Degree Award |
|
Peter Elyanu James
ID: UNCST-2021-R013210
|
GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children
REFNo: HS2708ES
This is a multisite, multi-cohort study that aims to recruit subjects in four weight-based cohorts (i.e. Cohort 1, 2, 3 and 4), with each cohort having specific objectives aligned with it. Baylor Uganda site will recruit subjects in cohort 4 with is further subdivided in 4 weight-based sub-groups. The study objectives in relation to the Cohort 4 are as follows;
Cohort 4
Group 1:
The primary objective of this study is:
• To evaluate the safety and tolerability of B/F/TAF 30/120/15 mg (administration of 2 B/F/TAF 15/60/7.5 mg FDC TOS) once daily through Week 24 in HIV-1 infected, virologically suppressed children ≥ 2 years of age weighing ≥ 14 to < 25 kg who are unable to swallow tablets
The secondary objectives of this study are:
• To evaluate the safety and tolerability of B/F/TAF 30/120/15 mg (administration of 2 B/F/TAF 15/60/7.5 mg FDC TOS) once daily through Week 48 in HIV-1 infected, virologically suppressed children ≥ 2 years of age weighing ≥ 14 to < 25 kg who are unable to swallow tablets
• To evaluate the antiviral activity of B/F/TAF 30/120/15 mg (administration of 2 B/F/TAF 15/60/7.5 mg FDC TOS) once daily through Weeks 24 and 48 in HIV-1 infected, virologically suppressed children ≥ 2 years of age weighing ≥ 14 to < 25 kg who are unable to swallow tablets
Group 2:
The primary objectives of this study are:
• To evaluate the steady state PK of BIC and TAF and confirm the dose of B/F/TAF 7.5/30/3.75 mg (administration of 2 B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 10 to < 14 kg
• To evaluate the safety and tolerability of B/F/TAF 7.5/30/3.75 mg (administration of 2 B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily through Week 24 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 10 to < 14 kg
The secondary objectives of this study are:
• To evaluate the safety and tolerability of B/F/TAF 7.5/30/3.75 mg (administration of 2 B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily through Week 48 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 10 to < 14 kg
• To evaluate the antiviral activity of B/F/TAF 7.5/30/3.75 mg (administration of 2 B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily through Weeks 24 and 48 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 10 to < 14 kg.
Group 3:
The primary objectives of this study are:
• To evaluate the steady state PK of BIC and TAF and confirm the dose of B/F/TAF 3.75/15/1.88 mg (administration of 1 B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 6 to < 10 kg
• To evaluate the safety and tolerability of B/F/TAF 3.75/15/1.88 mg (administration of 1 B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily through Week 24 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 6 to < 10 kg.
The secondary objectives of this study are:
• To evaluate the safety and tolerability of B/F/TAF 3.75/15/1.88 mg (administration of 1 B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily through Week 48 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 6 to < 10 kg
• To evaluate the antiviral activity of B/F/TAF 3.75/15/1.88 mg (administration of 1 × B/F/TAF 3.75/15/1.88 mg FDC TOS) twice daily through Weeks 24 and 48 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 6 to < 10 kg.
Group 4:
The primary objectives of this study are:
• To evaluate the steady state PK of BIC and TAF and confirm the dose of B/F/TAF 1.88/7.5/0.94 mg (administration of 1 B/F/TAF 1.88/7.5/0.94 mg FDC TOS) twice daily in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 3 to < 6 kg.
• To evaluate the safety and tolerability of B/F/TAF 1.88/7.5/0.94 mg (administration of 1 B/F/TAF 1.88/7.5/0.94 mg FDC TOS) twice daily through Week 24 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 3 to < 6 kg
The secondary objectives of this study are:
• To evaluate the safety and tolerability of B/F/TAF 1.88/7.5/0.94 mg (administration of 1 B/F/TAF 1.88/7.5/0.94 mg FDC TOS) twice daily through Week 48 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 3 to < 6 kg
• To evaluate the antiviral activity of B/F/TAF 1.88/7.5/0.94 mg (administration of 1 B/F/TAF 1.88/7.5/0.94 mg FDC TOS) twice daily through Weeks 24 and 48 in HIV-1 infected children ≥ 1 month of age, on ARV treatment or treatment naive, weighing ≥ 3 to < 6 kg
|
Uganda |
2023-03-16 12:47:17 |
2026-03-16 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|